A Study to Assess the Efficacy and Safety of DCC-2618 and Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumors After Treatment With Imatinib
Condition: Gastrointestinal Stromal Tumor(GIST) Interventions: Drug: Ripretinib; Drug: Sunitinib Sponsor: Zai Lab (Shanghai) Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials